Unified Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Unified Investment Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$235K	Buy	+745	New	+$176K	0.22%	127

Other funds holding LGND

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Pembroke Management Montreal, Quebec, Canada $637M AUM 40.98% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Unified Investment Management's LGND Position: Q2 2026 in Review

Unified Investment Management opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 745 shares worth $235K. The stake represents 0.22% of the portfolio and ranks #127 among its holdings.

132 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Unified Investment Management held 745 shares of Ligand Pharmaceuticals worth $235K as of Q2 2026.
Ligand Pharmaceuticals was a new Unified Investment Management position in Q2 2026.
Ligand Pharmaceuticals made up 0.22% of Unified Investment Management's portfolio in Q2 2026, its #127 holding.
132 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Unified Investment Management's 13F filing for Q2 2026, filed 27 Jul 2026.